ArticleIndian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India2025
Study of Cyclin D1 Expression in Squamous Cell Carcinoma of Oral Cavity.
Article in Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Salivary biomarkers in oral cancer diagnosis: advancing conventional treatment strategies.Military Medical Research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral Cavity Squamous Cell Carcinoma (OSCC) ranks 6th most common cancer across the world. Cyclin D1 regulates G1 to S phase of cell cycle. Its uncontrolled expression leads to excessive cell proliferation and neoplasia. This makes Cyclin D1 a possible biomarker for early diagnosis and management strategies. Fifty oral cavity histopathology specimens (10 benign lesions and 40 OSCC) were evaluated in a teaching hospital. Cyclin D1 expression was studied. Statistical significance (p value of ≥ 0.05 were considered insignificant) was calculated by Chi-Square and Mann-Whitney Wilcoxon test. We observed 15 well-differentiated Squamous cell carcinomas (WDSCC), 15 moderately-differentiated squamous cell carcinomas (MDSCC), 10 poorly-differentiated squamous cell carcinomas (PDSCC) amongst our cases of OSCC. Common sites were buccal mucosa (47.5%), tongue (35%) and tonsillar area (5%). All OSCC showed positivity for cyclin D1; while benign lesions exhibited immunoreactivity to cyclin D1 with mild staining of only < 10% cells. High Labeling Index (score 4) was seen more in PDSCC (70%) as compared to MDSCC (6.6%), WDSCC (00%). PDSCC showed strong intensity in 80% cases while only 20% MDSCC and 0% WDSCC cases had strong staining. Increase in Cyclin D1 immuno-reactivity is associated with decrease in cell-differentiation. Cyclin D1 may be a target for molecular based therapy leading to improved prognosis in OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.